IP Library Granted Patent US 10,828,320
Granted Patent B2
US 10,828,320 · App. 16/721,443 · Granted Nov 10, 2020

Ophthalmic compositions with improved dessication protection and retention

Inventors: James W. Davis (Falmouth, ME); Howard Allen Ketelson (Dallas, TX); Elaine E. Campbell (Shelton, CT); David L. Meadows (Colleyville, TX); Rekha Rangarajan (Fort Worth, TX)
Assignee: Alcon Inc.
A61K31/736A61K9/0048A61K31/728A61K47/02A61K47/10A61K47/26A61K47/32A61K47/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,828,320
App. No.
16/721,443
Granted
Nov 10, 2020
Kind
B2
Abstract

The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

Claims (7)

1. An ophthalmic composition comprising 0.17 to 0.18 w/v % hydroxypropyl guar, 0.15 w/v % sodium hyaluronate, and 1.4 w/v % sorbitol.

2. An ophthalmic composition according to claim 1 further comprising a borate, wherein said borate is boric acid.

3. An ophthalmic composition according to claim 1 further comprising a demulcent selected from the group consisting of: glycerin, polyvinyl pyrrolidone, polyethylene oxide, polyethylene glycol, propylene glycol, polyacrylic acid, and combinations thereof.

4. An ophthalmic composition according to claim 3 wherein said demulcent is polypropylene glycol or polyethylene glycol.

5. An ophthalmic composition according to claim 1 further comprising a pharmaceutically active compound.

6. An ophthalmic composition according to claim 1 , for use in treating ophthalmic disease.

7. An ophthalmic composition for use according to claim 6 , wherein the ophthalmic disease is dry eye.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2020
From: DAVIS, JAMES W.; KETELSON, HOWARD ALLEN; CAMPBELL, ELAINE E.; MEADOWS, DAVID L.; RANGARAJAN, REKHA
To: ALCON RESEARCH, LTD.
Reel/Frame 053174/0931 →
MERGER Recorded Jul 10, 2020
From: ALCON RESEARCH, LTD.
To: ALCON RESEARCH, LLC
Reel/Frame 053175/0036 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2020
From: ALCON RESEARCH, LLC
To: ALCON INC.
Reel/Frame 053175/0108 →